Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

On location

Adding Venetoclax to Azacitidine Improves Response and Survival Rates in Treatment-Naïve AML

A combination of the hypomethylating agent azacitidine and the small-molecule BCL2 inhibitor venetoclax was associated with a 34% reduction in the risk of death,...

Improving Access to Leukemia Treatment in Brazil

With more than 200 million people, Brazil has the largest population of any South American country and is currently the seventh most populous country...
On location

Evaluating MBG453 Plus Decitabine or Azacitidine in High-Risk MDS and AML

The anti-TIM-3 checkpoint inhibitor MBG453, when added to decitabine or azacitidine, was associated with antileukemic activity and durable response rates in patients with higher-risk...

FDA Grants Orphan Drug Designation to MT-401 for AML

The FDA has granted orphan drug designation to MT-401, an allogeneic T-cell therapy for the treatment of acute myeloid leukemia (AML). MT-401, from Marker Therapeutics,...
WIB_icon

Prophylaxis Does Not Fully Prevent VTE Risk in Patients With ALL Treated With Asparaginase

Antithrombin (AT) replacement and heparin prophylaxis was not entirely effective for the prevention of venous thromboembolism (VTE) in adult patients with acute lymphocytic leukemia...

FDA Approves Investigative New Drug Application for AUTO1 CAR-T Therapy for ALL

The FDA has accepted the Investigational New Drug (IND) application of CD19-targeting chimeric antigen receptor (CAR) T-cell therapy AUTO1 for the treatment of adults...

FDA Grants CC-486 (Oral Azacitidine) Priority Review for AML Maintenance

The FDA granted priority review status to CC-486 for maintenance treatment of adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR)...

UGT1A1*28 Genotype Is Associated With Reduced Overall Survival in Intermediate-Risk AML

Patients with intermediate-risk acute myeloid leukemia (AML) who are treated with cytarabine-based chemotherapy have lower overall survival (OS) if they possess the low-activity UGT1A1*28...

First Human Trial of Off-the-Shelf CAR T-Cell Therapy Shows Promise

Last month at the virtual annual meeting of the American Association for Cancer Research (AACR), Chinese researchers announced results from the first human trial...
On location

MLL Associated With Worse Post-Transplant Outcomes Than Other Cytogenetic Factors

In an analysis comparing the effects of MLL translocations with other cytogenetic characteristics on post-transplant outcomes in acute myeloid leukemia (AML), investigators found that...
Advertisement

Current Issue

Mid-January 2021 Annual Meeting Edition

This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.

Block title